Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioCryst Pharmaceuticals, Inc.    BCRX

News SummaryMost relevantAll newsSector newsTweets

BioCryst Pharmaceuticals, Inc. : Commentary & Reports For: (NASDAQ: BCRX), (NYSE: GST)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/24/2013 | 07:45pm CET

New York (April 24th, 2013) - BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) traded in the range of $1.75 and $1.97 during its latest trading session. The stock recorded the volume of 1.986 million shares. Currently, it is at $1.93, up 7.23 from its previous close. Its average daily trading volume stands at 1.085 million shares. Its MACD chart shows bullish trend and the stock is trading above its long term moving average price of $1.92. The company?s current market capitalization stands at $98.29 million.

BioCryst Pharmaceuticals stock is up 37.86 percent in the year 2013 so far while it lost 51.51 percent of its value in the past 52 weeks.

Find out if BCRX could maintain the momentum by getting the complete trend analysis report here:


Gastor Exploration Ltd. (NYSE: GST) stock is at $2.74, up 7.45 percent from its previous close of $2.55. The stock is up after the news of the company?s decision to sell its East Texas assets. Gastor Exploration shows bullish trend as it made the upward move with trading volume of 351,132 shares, in contrast to the average daily trading volume of 712,310 shares. Its bullish trend is further confirmed by its MACD chart and the stock is also trading above its 20 days SMA of $2.72.

Gastor Exploration stock is highly volatile with its beta at 1.57. The company?s market capitalization is at $186.18 million.

Get more news and reports on how to successfully trade GST here:



MonsterTradingAlerts.com issues momentum alerts on stocks that can provide gains to day traders. MonsterTradingAlerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. MonsterTradingAlerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals MonsterTradingAlerts.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the MonsterTradingAlerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.MonsterTradingAlerts.com

Disclosure: MonsterTradingAlerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit MonsterTradingAlerts.com website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit; http://www.monstertradingalerts.com/disclaimer/

Contact Info:
Alexander K. Neumann
Monster Trading Alerts
[email protected]

© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
11/20 BIOCRYST PHARMACEUTICALS : to Present at 29th Annual Piper Jaffray Healthcare Co..
11/16 BioCryst to Present at 29th Annual Piper Jaffray Healthcare Conference
11/10 BioCryst Reports Third Quarter 2017 Financial Results
11/07 BIOCRYST PHARMACEUTICALS, INC. (NASD : BCRX) Files An 8-K Results of Operations ..
11/07 BIOCRYST PHARMACEUTICALS INC : Results of Operations and Financial Condition, Re..
11/07 BIOCRYST PHARMACEUTICALS : reports 3Q loss
11/07 BioCryst Reports Third Quarter 2017 Financial Results
11/03 BIOCRYST PHARMACEUTICALS : to Present at the Jefferies 2017 London Healthcare Co..
11/01 BioCryst to Present at the Jefferies 2017 London Healthcare Conference
11/01 BIOCRYST PHARMACEUTICALS : Announces Late Breaker Presentation of BCX7353 Phase ..
More news
News from SeekingAlpha
11/16 YOUR DAILY PHARMA SCOOP : A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tu..
11/16 BioCryst Pharmaceuticals (BCRX) Presents At Jefferies 2017 London Healthcare ..
11/09 Planned equity offering roundup - healthcare
11/08 BioCryst Pharmaceuticals, Inc. 2017 Q3 - Results - Earnings Call Slides
11/07 BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q3 2017 Results - Ea..
Financials ($)
Sales 2017 26,3 M
EBIT 2017 -51,8 M
Net income 2017 -58,2 M
Debt 2017 100 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 21,2x
Capi. / Sales 2018 22,5x
Capitalization 457 M
Duration : Period :
BioCryst Pharmaceuticals,  Technical Analysis Chart | BCRX | US09058V1035 | 4-Traders
Technical analysis trends BIOCRYST PHARMACEUTICALS,
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 8,56 $
Spread / Average Target 84%
EPS Revisions
Jon P. Stonehouse President, Chief Executive Officer & Director
Robert Alexander Ingram Chairman
Robert Bennett Vice President-Investor Relations & Operations
Thomas R. Staab CFO, Treasurer, Principal Accounting Officer & SVP
William P. Sheridan Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB2.13%11 669
EXELIXIS, INC.75.25%7 731